IC Value
About Us
Editorial Board
Contact Us

In-hospital and mid-term clinical outcomes after percutaneous coronary intervention with drug eluting stents

Authors:Narasimha Pai D,Deepak R Madi,Basavaprabhu Achappa,Unnikrishnan B
Int J Biol Med Res. 2012; 3(4): 2527-2530  |  PDF File


Background and objective-Sirolimus-eluting (SES) and paclitaxel-eluting (PES) stents are first generation drug-eluting stents (DES) used to treat patients with ischemic heart disease. Drug-eluting stents (DES) have reduced the occurrence of restenosis and major adverse cardiac events (MACE) when compared with bare metal stents. Our aim was to assess the safety and mid-term clinical outcomes of stenting with Sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) for the treatment of coronary artery disease in our routine practice. Material and methods- The study population consisted of 100 patients who had undergone drug eluting stent implantation. Patients were eligible for enrollment if they had symptomatic coronary artery disease or positive exercise testing, and angiographic evidence of single or multivessel disease with a target lesion stenosis of ≥ 70%. Patients were followed-up for 6 months. The efficacy and safety of the procedure, in-hospital clinical outcome and the occurrence of major adverse cardiac events in the first 6 months were assessed. Statistical analysis was done. Results-All patients survived after stent implantation.1 (1%) patient experienced acute ST elevation myocardial infarction during follow up. Recurrent angina pectoris was observed in 5 (5%) patients (2 stable angina pectoris and 3 unstable angina pectoris).The 6month rate of MACE in our study was 1%. Conclusion-The results of the present study indicate that drug eluting stents could be implanted with a very high success rate and have encouraging mid-term clinical results.